Market openNon-fractional

Adverum Biotechnologies/ADVM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Ticker

ADVM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Redwood city, United States

Employees

121

ADVM Metrics

BasicAdvanced
$164M
Market cap
-
P/E ratio
-$10.23
EPS
1.13
Beta
-
Dividend rate
$164M
1.13
$29.70
$7.24
6.7
9.241
-41.55%
-66.40%
-47.50%
0.902
0.902
-100.00%
30.06%

What the Analysts think about ADVM

Analyst Ratings

Majority rating from 7 analysts.
Buy

ADVM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
4.22%
Profit margin
0.00%
NaN%

ADVM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.79%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.10
-$3.30
-$2.30
-$1.50
-
Expected
-$3.29
-$3.15
-$3.37
-$1.40
-$1.52
Surprise
-5.72%
4.71%
-31.68%
6.79%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Adverum Biotechnologies stock?

Adverum Biotechnologies (ADVM) has a market cap of $164M as of July 23, 2024.

What is the P/E ratio for Adverum Biotechnologies stock?

The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of July 23, 2024.

Does Adverum Biotechnologies stock pay dividends?

No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Adverum Biotechnologies dividend payment date?

Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.

What is the beta indicator for Adverum Biotechnologies?

Adverum Biotechnologies (ADVM) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Adverum Biotechnologies stock

Buy or sell Adverum Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing